PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.
BionicBell discussed using Bimatoprost, a medication typically for eyelash growth, for hair loss and mentioned a compounding pharmacy that can mix it with other ingredients like minoxidil and finasteride. They are seeking advice on using topical finasteride for female pattern baldness and are considering a custom foam combination to maximize hair growth results.
The effectiveness of microneedling as a hair loss treatment, with evidence from studies and anecdotal accounts from other users. It is suggested that combining microneedling with minoxidil or finasteride may be more effective than using microneedling alone, although some people have had success using only microneedling.
An 18-year-old diagnosed with male pattern baldness is using probiotics, saw palmetto, pumpkin seed oil, soy isoflavones, biotin, fish oil, quercetin, a multivitamin, and ketoconazole shampoo. Replies suggest these methods are ineffective and recommend finasteride, minoxidil, and a derma roller.
A user's experience with Pyrilutamide for hair loss, which has been successful in reversing receding hairline when part of their stack with other treatments such as Dutasteride, Minoxidil, and Ketoconazole shampoo.
A user who underwent a hair transplant in Istanbul to reduce balding, and the discussion of various treatments such as finasteride and growth hormone for preventing further hair loss.
Creatine may increase DHT levels, potentially causing symptoms like acne, oily hair, and hair shedding. Users report mixed experiences, with some avoiding creatine due to hair loss concerns and others seeing no impact.
User added RU and pyrilutamide for hair growth and noticed more baby hairs. Others suggest sticking with fin and min, while some discuss the user's self-image and hair loss severity.
The user is experiencing significant hair loss despite using treatments like finasteride, minoxidil, dutasteride, micro-needling, rosemary oil, and various vitamins. In the conversation, others suggest checking iron and hemoglobin levels, maintaining a positive attitude, and adding RU58841 to the treatment regimen.
Stopping minoxidil causes significant hair loss, as continued use is necessary for maintaining gains. Combining minoxidil with finasteride may help maintain hair, but both treatments are typically lifelong commitments.
Topical dutasteride may be effective for hair loss by staying in the scalp and minimizing bloodstream absorption, potentially improving hair results and reducing side effects. The user seeks advice on its effectiveness.
The post and conversation are about a 23-year-old deciding to stop using finasteride for hair loss due to potential erectile dysfunction risks, sparking a debate about the benefits and side effects of hair loss treatments.
Finasteride can cause sexual side effects in less than 2% of men, but these often disappear over time, even if the treatment continues. Some users report persistent side effects, while others experience no issues or only temporary ones.
Treatments for hair loss, including Minoxidil, finasteride, and RU58841. The post discusses the potential benefits of Pyrilutamide compared to RU58841 in terms of strength and longevity.
A compound called MTP3 from the Monoterpene family was found to be safe and highly effective at treating hair loss by inhibiting the FGF5 gene, but its identity is undisclosed for commercial reasons. No specific treatments like Minoxidil, finasteride, or RU58841 were discussed.
The user is seeking advice for the best topical treatment to combat their ongoing hair loss, despite already using oral dutasteride, RU-58841, and minoxidil. They are considering adding CB-03-01 or topical Spiro to their regimen to lower testosterone levels at the follicles.
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
The conversation is about compounding topical cyclosporine for hair loss, suggesting it needs an oil base like castor oil. The user seeks tips or tricks for the process.
The user, on testosterone replacement therapy, found finasteride and minoxidil ineffective for hair loss. They are trying a new topical gel with dutasteride, tretinoin, and a higher concentration of minoxidil, and plan to document the results.
The conversation is about DIY Dutasteride mesotherapy for hair loss, focusing on creating an injectable treatment to target the scalp and limit side effects. The user seeks feedback on enhancing the treatment with additional ingredients.
User is asking for progress on hair regrowth after 6 months of using oral finasteride and minoxidil tablets. Replies suggest good results and recommend using dutasteride instead of finasteride for severe hair loss.
A user shared progress pictures after 50 days of using a compound with 10% minoxidil, 0.1% finasteride, and biotin, expressing satisfaction with the results. Another user commented positively on the progress.
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
A natural compound called C3A from Aronia Chokeberry can help prevent hair loss by counteracting the effects of DHT. The user has been taking 50 grams of dried organic Aronia Chokeberry daily for 30 days and will update with photos in 60 days.
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
A group buy for testing a compound targeting Twist1 protein as a potential hair loss treatment. Inhibiting Twist1, which keeps hair follicles in growth phase, may prevent hair loss with minimal side effects.
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.